# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $29 price target.
– Cabozantinib continues to demonstrate a significant improvement in progression-free survival versus placebo in patients with ...
Exelixis, Inc. (NASDAQ:EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal st...
Truist Securities analyst Asthika Goonewardene reiterates Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from...
JMP Securities analyst Silvan Tuerkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and raises the price target...
Exelixis reports strong Q2 earnings with adjusted EPS of $0.84, surpassing estimates. The CONTACT-02 trial for mCRPC showed sig...
RBC Capital analyst Gregory Renza reiterates Exelixis (NASDAQ:EXEL) with a Outperform and maintains $27 price target.